Morbidity and costs of salvage vs. primary radical prostatectomy in older men

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1477-1482

  Prasad, Sandip M ^a   Gu, Xiangmei ^b   Kowalczyk, Keith J ^c   Lipsitz, Stuart R ^b   Nguyen, Paul L ^b   Hu, Jim C ^d  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Outcomes; Radiotherapy; Salvage prostatectomy; Utilization

Indexed keywords

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SPECIFIC SURVIVAL; HEALTH CARE COST; HEART DISEASE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATECTOMY; RESPIRATORY TRACT DISEASE; SALVAGE THERAPY; SURGICAL MORTALITY; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; WOUND;

OUTCOMES; RADIOTHERAPY; SALVAGE PROSTATECTOMY; UTILIZATION;

AGED; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICARE; MORBIDITY; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; SEER PROGRAM; UNITED STATES;

EID: 84886237228     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.004     Document Type: Article

References (35)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
2. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277:1445-1451.
3. Galper S.L., Chen M.H., Catalona W.J., et al. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006, 175:907-912.
4. Cooperberg M.R., Broering J.M., Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28:1117-1123.
5. Agarwal P.K., Sadetsky N., Konety B.R., et al. Treatment failure after primary and salvage therapy for prostate cancer: Likelihood, patterns of care, and outcomes. Cancer 2008, 112:307-314.
6. Van Hemelrijck M., Adolfsson J., Garmo H., et al. Risk of thromboembolic diseases in men with prostate cancer: Results from the population-based PCBaSe Sweden. Lancet Oncol 2010, 11:450-458.
7. Keating N.L., O'Malley A.J., Freedland S.J., et al. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102:39-46.
8. Grossfeld G.D., Li Y.P., Lubeck D.P., et al. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: Data from cancer of the prostate strategic urologic research endeavor. J Urol 2002, 168:530-535.
9. Lerner S.E., Blute M.L., Zincke H. Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995, 154:1103-1109.
10. Rogers E., Ohori M., Kassabian V.S., et al. Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 1995, 153:104-110.
11. Bianco F.J., Scardino P.T., Stephenson A.J., et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62:448-453.
12. Chade D.C., Eastham J., Graefen M., et al. Cancer control and functional outcomes of salvage radical prostatectomy for Radiation-recurrent prostate cancer: A systematic review of the literature. Eur Urol 2012, 61:961-971.
13. Warren J.L., Klabunde C.N., Schrag D., et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002, 40:IV-3-18.
14. Klabunde C.N., Potosky A.L., Legler J.M., et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000, 53:1258-1267.
15. Begg C.B., Riedel E.R., Bach P.B., et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002, 346:1138-1144.
16. Rao J.N.K., Scott A.J. The analysis of categorical-data from complex sample-surveys - Chi-squared tests for goodness of fit and independence in 2-way tables. JASA 1981, 76:221-230.
17. Rosenbaum P.R., Rubin D.B. Reducing bias in observational studies using subclassification on the propensity score. JASA 1984, 79:516-524.
18. Rubin D.B. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
19. Robins J.M., Hernán M.A., Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000, 11:550-560.
20. Rainwater L.M., Zincke H. Radical prostatectomy after radiation therapy for cancer of the prostate: Feasibility and prognosis. J Urol 1988, 140:1455-1459.
21. Mador D.R., Huben R.P., Wajsman Z., et al. Salvage surgery following radical radiotherapy for adenocarcinoma of the prostate. J Urol 1985, 133:58-60.
22. Vaidya A., Soloway M.S. Salvage radical prostatectomy for radiorecurrent prostate cancer: Morbidity revisited. J Urol 2000, 164:1998-2001.
23. Ward J.F., Sebo T.J., Blute M.L., et al. Salvage surgery for radiorecurrent prostate cancer: Contemporary outcomes. J Urol 2005, 173:1156-1160.
24. Chade D.C., Shariat S.F., Cronin A.M., et al. Salvage radical prostatectomy for Radiation-recurrent prostate cancer: A multi-institutional collaboration. Eur Urol 2011, 60:205-210.
25. Chauhan S., Patel M.B., Coelho R., et al. Preliminary analysis of the feasibility and safety of salvage robot-assisted radical prostatectomy after radiation failure: Multi-institutional perioperative and short-term functional outcomes. J Endourol 2011, 25:1013-1019.
26. Mottet N., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011, 59:572-583.
27. Mohler J., Bahnson R.R., Boston B., et al. NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Cancer Netw 2010, 8:162-200.
28. Prasad S.M., Gu X., Lipsitz S.R., et al. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer 2012, 118:1260-1267.
29. Chade D.C., Shariat S.F., Cronin A.M., et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: A multi-institutional collaboration. Eur Urol 2011, 60:205-210.
30. Touma N.J., Izawa J.I., Chin J.L. Current status of local salvage therapies following radiation failure for prostate cancer. J Urol 2005, 173:373-379.
31. D'Amico A.V., Cote K., Loffredo M., et al. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003, 170:S42-S46. Discussion: S6-7.
32. Heidenreich A., Richter S., Thüer D., et al. Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy. Eur Urol 2010, 57:437-443.
33. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004, 172:2239-2243.
34. Lawthers A.G., McCarthy E.P., Davis R.B., et al. Identification of in-hospital complications from claims data. Is it valid?. Med Care 2000, 38:785-795.
35. Glenny A.M., Altman D.G., Song F., et al. Indirect comparisons of competing interventions. Health Technol Assess 2005, 9:1-148.